Aug 13
ELDN · Eledon Pharmaceuticals, Inc. · Documents
$2.62
+0.00 (+0.00%)
At close · Nov 3
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plan, the Company expects that, within the next twelve months, its existing cash, cash equivalents, short-term investments and other available resources will not be sufficient to fund its planned operations and satisfy its obligations as they become due unless it obtains additional financing. Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Although management intends to obtain additional financing through the sources described above, these plans are subject to market conditions and other factors outside the Company's control. Accordingly, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$212.90M
Shares
81.26M
Volume · Nov 3
403.17K
Avg daily vol (3M)
913.96K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Aug 13
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Net loss $31.63M
Diluted EPS -$0.27
Jun 22
Current report
8-K
Events of Jun 18
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
AI summary on its way
May 13
May 13
Quarterly report
10-Q
FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1
AI summary on its way
Net loss $39.03M
Diluted EPS -$0.33
May 1
Apr 30
Apr 30
Apr 30
Apr 21
Mar 19
Mar 19
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Net loss $45.62M
Diluted EPS -$0.52
Jan 2
2025
Nov 14
Current report
8-K
Financial results
Nov 14
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Net loss $17.46M
Diluted EPS -$0.21
Nov 13
Current report
8-K
Events of Nov 12
Entered into a material agreement
Nov 7
Current report
8-K
Events of Nov 6
Financial results, Regulation FD disclosure
Aug 14
Quarterly report
10-Q/A
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Net loss $6.5M
Diluted EPS -$0.08
Aug 14
Aug 14
Current report
8-K
Events of Aug 11
Financial results, Earlier financial statements no longer reliable
Aug 14
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Net loss $11.22M
Diluted EPS -$0.13
Aug 6
Current report
8-K
Regulation FD disclosure
Jun 12
Current report
8-K
Events of Jun 10
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
May 14
Current report
8-K
Financial results
May 14
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Net loss $6.5M
Diluted EPS -$0.08
Apr 29
Proxy statement
DEF 14A
Meeting Jun 10, 2025
Proxy statement
Apr 29
Annual report to holders
ARS
Annual report to holders
Apr 29
Proxy statement
DEFA14A
Proxy statement
Apr 14
Current report
8-K/A
Events of Apr 1
Change of auditor
Apr 14
Proxy statement
PRE 14A
Meeting Jun 10, 2025
Proxy statement
Apr 7
Current report
8-K
Events of Apr 1
Change of auditor
Mar 20
Current report
8-K
Financial results
Mar 20
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Net loss $36.18M
Diluted EPS -$0.75
2024
Dec 20
Current report
8-K
Events of Dec 16
Director or officer change, or executive pay
Nov 12
Current report
8-K
Financial results
Nov 12
Quarterly report
10-Q
FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Net income $76.97M
Diluted EPS -$0.32
Oct 30
Current report
8-K
Events of Oct 29
Entered into a material agreement, Regulation FD disclosure
Oct 29
Current report
8-K
Regulation FD disclosure
Oct 1
Current report
8-K
Events of Sep 30
Unregistered sale of equity
Sep 20
Current report
8-K
Entered into a material agreement
Sep 20
Registration statement
S-3
Registration statement
Aug 19
Quarterly report
10-Q/A
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Net loss $23.63M
Diluted EPS -$0.79
Aug 19
Annual report
10-K/A
FY2023, ended Dec 31
Annual report for FY2023
Net loss $116.54M
Diluted EPS -$4.73
Aug 19
Quarterly report
10-Q
FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Net loss $44.91M
Diluted EPS -$1.06
Aug 14
Current report
8-K
Events of Aug 13
Financial results, Earlier financial statements no longer reliable
Aug 14
Late filing notice
NT 10-Q
Late filing notice
Jul 12
Current report
8-K
Events of Jul 10
Change of auditor
Jul 10
Jul 10
Current report
8-K
Events of Jul 8
Unregistered sale of equity
May 30
Proxy statement
DEF 14A
Meeting Jul 10, 2024
Proxy statement
Showing 1–50 of 146 documents
Key facts
CIK
1404281
CUSIP
28617K101
13F (30d)
45 filings
44 filers
Visit website
Investor relations